KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Deffered Revenue (2016 - 2023)

NovoCure's Non-Current Deffered Revenue history spans 9 years, with the latest figure at $807000.0 for Q2 2023.

  • For Q2 2023, Non-Current Deffered Revenue fell 82.23% year-over-year to $807000.0; the TTM value through Jun 2023 reached $807000.0, down 82.23%, while the annual FY2022 figure was $2.9 million, 55.57% down from the prior year.
  • Non-Current Deffered Revenue for Q2 2023 was $807000.0 at NovoCure, down from $1.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $12.1 million in Q4 2020 and bottomed at $807000.0 in Q2 2023.
  • The 5-year median for Non-Current Deffered Revenue is $7.9 million (2019), against an average of $7.0 million.
  • The largest annual shift saw Non-Current Deffered Revenue surged 55.49% in 2020 before it tumbled 82.23% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $7.8 million in 2019, then soared by 55.49% to $12.1 million in 2020, then tumbled by 46.64% to $6.5 million in 2021, then plummeted by 55.57% to $2.9 million in 2022, then tumbled by 71.96% to $807000.0 in 2023.
  • Per Business Quant, the three most recent readings for NVCR's Non-Current Deffered Revenue are $807000.0 (Q2 2023), $1.8 million (Q1 2023), and $2.9 million (Q4 2022).